The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo

Frank P. Vendetti, Alan Lau, Sandra Schamus, Thomas P. Conrads, Mark J. O'Connor, Christopher J. Bakkenist*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

197 Scopus citations

Fingerprint

Dive into the research topics of 'The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo'. Together they form a unique fingerprint.

Medicine & Life Sciences